{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:10:40Z","timestamp":1793070640570,"version":"4.5.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The calreticulin (\n                      <jats:italic>CALR<\/jats:italic>\n                      ) exon 9 mutations that are identified in 20% of patients with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) generate immunogenic antigens. Thus, therapeutic cancer vaccination against mutant CALR could be a new treatment modality in\n                      <jats:italic>CALR<\/jats:italic>\n                      -mutant MPN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The safety and efficacy of vaccination with the peptide CALRLong36 derived from the\n                      <jats:italic>CALR<\/jats:italic>\n                      exon 9 mutations was tested in a phase I clinical vaccination trial with montanide as adjuvant. Ten patients with\n                      <jats:italic>CALR<\/jats:italic>\n                      mut MPN were included in the trial and received 15 vaccines over the course of one year. The primary end point was evaluation of safety and toxicity of the vaccine. Secondary endpoint was assessment of the immune response to the vaccination epitope (\n                      <jats:uri>www.clinicaltrials.gov<\/jats:uri>\n                      identifier NCT03566446).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients had a median age of 59.5 years and a median disease duration of 6.5 years. All patients received the intended 15 vaccines, and the vaccines were deemed safe and tolerable as only two grade three AE were detected, and none of these were considered to be related to the vaccine. A decline in platelet counts relative to the platelets counts at baseline was detected during the first 100 days, however this did not translate into neither a clinical nor a molecular response in any of the patients. Immunomonitoring revealed that four of 10 patients had an\n                      <jats:italic>in vitro<\/jats:italic>\n                      interferon (IFN)-\u03b3 ELISPOT response to the CALRLong36 peptide at baseline, and four additional patients displayed a response in ELISPOT upon receiving three or more vaccines. The amplitude of the immune response increased during the entire vaccination schedule for patients with essential thrombocythemia. In contrast, the immune response in patients with primary myelofibrosis did not increase after three vaccines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Therapeutic cancer vaccination with peptide vaccines derived from mutant\n                      <jats:italic>CALR<\/jats:italic>\n                      with montanide as an adjuvant, is safe and tolerable. The vaccines did not induce any clinical responses. However, the majority of patients displayed a marked T-cell response to the vaccine upon completion of the trial. This suggests that vaccines directed against mutant CALR may be used with other cancer therapeutic modalities to enhance the anti-tumor immune response.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2021.637420","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:21:41Z","timestamp":1614306101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms"],"prefix":"10.3389","volume":"11","author":[{"given":"Jacob","family":"Handlos Grauslund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Orebo","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai Gr\u00f8nne","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe","family":"Klausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Emilie","family":"Weis-Banke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"El Fassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sch\u00f6llkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Borg","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Mette Rahbek","family":"Gjerdrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Fredslund","family":"Breinholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Westerlin","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chatain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy Wayne","family":"Novotny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zcan","family":"Met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra063728","article-title":"The Myeloproliferative Disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544.The","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61664-9","article-title":"Essential Thrombocythemia Beyond the First Decade : Life Expectancy, Long-term Complication Rates, and Prognostic Factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An olmsted county study, 1976-1995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1856.Supported","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1049171","article-title":"Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","volume":"57","author":"Rank","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2015","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-014-0227-0","article-title":"An Immune Dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071763","article-title":"Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms","volume":"12","author":"Holmstr\u00f6m","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT Signaling in Immunity and Disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113","article-title":"A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Holmstrom","year":"2018","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Holmstr\u00f6m","year":"2016","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"B27","article-title":"CD4+ T-Cell Immunity to Mutated ras Protein in Pancreatic and Colon Cancer Patients","volume":"55","author":"Qin","year":"1995","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(92)90334-J","article-title":"T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides","volume":"33","author":"Gedde-Dahl","year":"1992","journal-title":"Hum Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/BF01517348","article-title":"CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13\u2013>Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation","volume":"40","author":"Fossum","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)92408-6","article-title":"Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation","volume":"346","author":"Gjertsen","year":"1995","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-12-55","article-title":"The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors","volume":"12","author":"Rahma","year":"2014","journal-title":"J Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0477-6","article-title":"Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers","volume":"57","author":"Toubaji","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25449","article-title":"Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras","volume":"128","author":"Wed\u00e9n","year":"2011","journal-title":"Int J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.478","article-title":"Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome","volume":"23","author":"de Vries","year":"2005","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3390\/cancers12103045","article-title":"Healthy donors harbor memory T cell responses to RAS neo-antigens","volume":"12","author":"Holmstr\u00f6m","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0875-4","article-title":"Response definition criteria for ELISPOT assays revisited","volume":"59","author":"Moodie","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.595035","article-title":"Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma : A Phase I First-in-Human Trial","volume":"11","author":"J\u00f8rgensen","year":"2020","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.02.010","article-title":"Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"79","author":"Wang","year":"2019","journal-title":"Leuk Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms","volume":"9","author":"Bozkus","year":"2019","journal-title":"Cancer Discov"},{"key":"B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199903000-00007","article-title":"A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors","volume":"22","author":"Khleif","year":"1999","journal-title":"J Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1792","article-title":"NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome","volume":"24","author":"Griffiths","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-394395.There","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia","volume":"97","author":"Greiner","year":"2016","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2671","article-title":"Is the \u201c3+3\u201d dose-escalation Phase i Clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design","volume":"20","author":"Rahma","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2016.254","article-title":"PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies","volume":"31","author":"Qazilbash","year":"2017","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e1433521","DOI":"10.1080\/2162402X.2018.1433521","article-title":"Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response","volume":"7","author":"Holmstr\u00f6m","year":"2018","journal-title":"Oncoimmunology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1468957","article-title":"Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation","volume":"7","author":"Aaboe-J\u00f8rgensen","year":"2018","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"Oncoimmunology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0166-4","article-title":"High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals","volume":"9","author":"Holmstr\u00f6m","year":"2019","journal-title":"Blood Cancer J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3246","article-title":"The determinants of tumour immunogenicity","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.002836","article-title":"Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I","volume":"293","author":"Arshad","year":"2018","journal-title":"J Biol Chem"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2479","article-title":"Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma","volume":"72","author":"Aarntzen","year":"2012","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1359743","article-title":"Sorted Peripheral Blood Cells Identify CALR Mutations in B- and T-lymphocytes","volume":"59","author":"Kjaer","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: Function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-\u03b1","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12420","article-title":"Expansion of circulating CD56(bright) natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1","volume":"94","author":"Riley","year":"2015","journal-title":"Eur J Haematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0275-0","article-title":"Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion","volume":"9","author":"Han","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2019.11.004","article-title":"Immunosuppression by Mutated Calreticulin Released from Malignant Cells","volume":"77","author":"Liu","year":"2020","journal-title":"Mol Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5860657","DOI":"10.1155\/2016\/5860657","article-title":"Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly","volume":"2016","author":"Sollazzo","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1262032","article-title":"The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms","volume":"58","author":"Skov","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12013","article-title":"Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting","volume":"159","author":"Klyuchnikov","year":"2012","journal-title":"Br J Haematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.6183","article-title":"Donor Lymphocyte Infusion Induces Polyspecific CD8+ T-Cell Responses With Concurrent Molecular Remission in Acute Myeloid Leukemia With NPM1 Mutation","volume":"31","author":"Hofmann","year":"2013","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Sch\u00f6nberg","year":"2015","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1021\/ac901991x","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana","year":"2015","journal-title":"Br J Haematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-016-0593-x","article-title":"Anti-regulatory T cells","volume":"39","author":"Andersen","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3507","article-title":"HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients","volume":"73","author":"Munir","year":"2013","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1390641","article-title":"The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy","volume":"7","author":"Ahmad","year":"2017","journal-title":"Oncoimmunology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e1404215","DOI":"10.1080\/2162402X.2017.1404215","article-title":"Frequent adaptive immune responses against arginase-1","volume":"7","author":"Martinenaite","year":"2017","journal-title":"Oncoimmunology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1771142","article-title":"The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines","volume":"9","author":"Weis-Banke","year":"2020","journal-title":"Oncoimmunology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e34568","DOI":"10.1371\/journal.pone.0034568","article-title":"Natural CD4 + T-cell responses against indoleamine 2,3-dioxygenase","volume":"7","author":"Munir","year":"2012","journal-title":"PLoS One"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1560","article-title":"Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase","volume":"20","author":"Iversen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"S1176","DOI":"10.1016\/j.annonc.2020.08.2278","article-title":"LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO\/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I\/II trial","volume":"31","author":"Svane","year":"2020","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00281-018-0695-8","article-title":"The T-win\u00ae technology: immune-modulating vaccines","volume":"41","author":"Andersen","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and Calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02473-y","article-title":"Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer","volume":"69","author":"Holmstr\u00f6m","year":"2020","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.637420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:21:54Z","timestamp":1614306114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.637420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":97,"alternative-id":["10.3389\/fonc.2021.637420"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.637420","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"article-number":"637420"}}